A positive hepatitis B result can raise an immediate question: will treatment begin now? The answer depends on what further tests show about the infection and the liver. We approach hepatitis B treatment guidelines as tools for a conversation between patients and qualified clinicians, rather than instructions for choosing medication from a laboratory report. Understanding a few common results can make that conversation clearer and help people return for the care they need.
A screening result identifies a reason to investigate. Hepatitis B surface antigen (HBsAg) can indicate a current infection, but clinicians must also interpret other markers and the person's medical history. A common initial blood-testing panel includes HBsAg, surface antibody (anti-HBs) and core antibody (anti-HBc). Their combined pattern can help distinguish current infection, past infection and vaccine-related immunity.
Chronic hepatitis B requires a more complete assessment. Previous laboratory records, follow-up testing and the duration of infection can matter; persistence of HBsAg for six months is an established indicator of chronic infection. One result cannot tell someone how much liver damage has occurred or whether antiviral treatment should begin.
Once a clinician establishes the clinical picture, several measurements help answer different questions. None provides the full answer in isolation. The most useful approach considers laboratory results alongside symptoms, prior records and examination findings.
| Result | What it helps assess |
|---|---|
| HBV DNA (viral load) | Measures the amount of viral genetic material in blood; helps assess viral activity and follow response over time. |
| ALT (liver enzyme) | Can signal liver-cell injury. Clinicians consider repeated values because levels change and other conditions also affect ALT. |
| HBeAg and related markers | Help characterize the phase of HBV infection. A negative HBeAg result does not automatically mean the virus is inactive. |
| Fibrosis and cirrhosis assessment | Tests such as elastography or blood-based fibrosis scores help assess liver scarring; clinical findings remain important. |
These tests answer separate questions about viral replication, inflammation and liver structure. A high viral load does not, by itself, measure the degree of scarring. Equally, a single normal ALT result cannot replace follow-up when other findings suggest continued risk.
The World Health Organization’s 2026 consolidated hepatitis guidance brings together recommendations on testing, treatment eligibility and monitoring. Its public-health approach aims to improve access to assessment while accounting for factors such as liver disease severity and the availability of tests.
The AASLD/IDSA hepatitis B practice guideline, published online in 2025 and in its final journal issue in 2026, addresses particular clinical decisions, including uncertain phases of chronic infection, prevention of transmission and surveillance. These documents have different scopes. Neither turns one laboratory number into a universal rule for every person or every health system.
A clinician weighs the overall evidence, explains whether treatment is appropriate and discusses the next review date. Patients should ask which findings are driving that recommendation.
Some situations call for additional review even when routine results seem straightforward. During pregnancy, clinicians assess HBV status and the need to reduce transmission to the baby. Suspected cirrhosis can change the urgency of evaluation and the approach to treatment.
Coinfection, including hepatitis D (HDV), can affect assessment and care. Medicines that suppress the immune system may also create a risk of HBV reactivation, making past infection history relevant. These circumstances warrant individualized advice rather than a decision based on an online checklist.
A decision to monitor without starting medication still requires a plan. Chronic HBV can change over time. Clinicians may repeat ALT and HBV DNA tests, reassess fibrosis and consider surveillance for liver cancer when a person's risk warrants it. Follow-up intervals depend on the disease stage, previous findings and whether treatment has begun.
Before leaving an appointment, it helps to clarify who will review new results and how the next visit will be arranged. Missing a follow-up can leave a meaningful change in liver health unnoticed.
We encourage people to leave a clinical visit with answers they can use. These four questions offer a practical starting point:
Through our hepatitis B outreach work, we emphasize clear information, testing and connection with qualified care. The foundation's education role does not replace an individual medical assessment. This resource is for education only and does not replace evaluation or treatment advice from a qualified healthcare professional.
